Singapore, Nov. 2 -- Merck, a leading science and technology company, has opened its new Asia-Pacific Bioprocessing Production Centre in Daejeon, South Korea. The centre represents an investment of more than €300 million, the company's largest Life Science investment in Asia-Pacific to date.

The 44,500-square-meter site expands the Merck's regional manufacturing capacity for critical materials and solutions used in the development and production of biologic medicines. It gives biopharmaceutical manufacturers across Asia-Pacific closer access to the materials and solutions needed to develop and produce biologic medicines.

From Daejeon, Merck will supply bioprocessing products used from early process development through commercial-s...